Prof Martin Reck speaks to ecancer about pembrolizumab plus concurrent chemoradiation therapy (cCRT) in unresectable locally advanced Non-Small-Cell Lung Cancer (NSCLC).

KEYNOTE-799 is a phase two trial exploring pembrolizumab combined with chemoradiotherapy for unresectable stage three non-small cell lung cancer.

Patients were split into two cohorts, receiving different chemotherapy regimens.

The trial prioritised safety and efficacy, revealing low pulmonary toxicity and a response rate of over 70%.

After five years, median progression-free survival was 29 to 45 months, and overall survival ranged from 30.35 to 52.7 months, paving the way for a phase three trial.